posted 03-06-2008 11:04 PM            

This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced ninety-seven (97) new catalog peptides.

[NMeG24; NMeI26] Human Islet Amyloid Polypeptide (IAPP) (22-27)- Cat# 61937
This amino acids 22 to 27 fragment is a modification of the human islet amyloid polypeptide hIAPP (NFGAIL) with N-methylation of the amide bonds at G24 and I26. The introduction of two N-methyl rests in the amyloid-core-containing sequence NFGAIL converts this amyloidogenic and cytotoxic sequence into non-amyloidogenic and non-cytotoxic peptide. The peptide is able to bind with high-affinity full-length hIAPP and to inhibit its fibrillogenesis.
Sequence: NF-(NMe-G)-A-(NMe-I)-L

[Ala20]-beta-Amyloid (1-42)- Cat# 62446
This is a modified beta-Amyloid (1-42); with Phe20 replaced by Ala20.
Sequence: DAEFRHDSGYEVHHQKLVFAAEDVGSNKGAIIGLMVGGVVIA

[Cys40]-beta-hairpin (BHA); Protein G B1 Domain (41-56)- Cat# 62533
This ?-hairpin (BHA) peptide is amino acid residues 41 to 56 fragment from the B1 domain of protein G. BHA peptide adopts a stable ?-hairpin structure in aqueous solution with a population of ~40%. In water; BHA adopts a twisted conformation around the peptide axis. In 30% (vol/vol) TFE/water solution; the ?-hairpin population further increases up to ~60%. This peptide also contains a Cys on the N-terminus of the peptide.
Sequence: CGEWTYDDATKTFTVTE

[Gly22] beta-Amyloid (1-42); Arctic Mutation- Cat# 61967-05
This is amino acids 1 to 40 fragment of the mutant form of beta-amyloid; with glycine substituted for glutamic acid at position 22 found in “Arctic” heredity. A toxic soluble beta-amyloid assembly (TA-beta) is formed more rapidly from 'Arctic' beta-amyloid than from wild-type beta-amyloid in the presence of liposomes containing GM1 ganglioside.
Sequence: DAEFRHDSGYEVHHQKLVFFAGDVGSNKGAIIGLMVGGVVIA

[Lys22] Beta-Amyloid (1-42); E22K; Italian Mutation- Cat# 62148
This is amino acids 1 to 42 fragment of the beta-amyloid peptide; with lysine substituted for glutamic acid at position 22 found in Italian families with Alzheimer's disease. The Italian mutation of beta -amyloid 1 to 42 (E22K) aggregates more rapidly and with more potent neurotoxicity than wild-type beta-amyloid (1-42). The formation of a salt bridge between Lys22 and Asp23 in the minor conformer might be a reason why E22K is more pathogenic than wild-type beta-amyloid (1-42).
Sequence: DAEFRHDSGYEVHHQKLVFFAKDVGSNKGAIIGLMVGGVVIA

5-FAM-beta-Amyloid (1-40)-Lys(LC-biotin); amide- Cat# 61962-01
This is a 5-FAM labeled ß-?Amyloid (1-40). This amidated peptide is also biotinylated on the lysine side chain with 6-aminohexanoate (LC) as a spacer; Ex/Em=490 nm/ 520 nm.
Sequence: 5-FAM-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-K(LC-BIOTIN)-NH2

Amyloid Precursor Protein; (APP) (667-676); FRET peptide- Cat# 62075
This amino acids 667 to 676 fragment of the amyloid precursor protein (APP) is a beta secretase substrate containing an Mca/ Dap(Dnp) FRET pair. Beside being cleaved by beta-site APP cleavage enzyme (BACE) between the Met and Asp residues; it can also be cleaved by the enzyme thimet oligopeptidase (TOP); Ex/Em=330 nm/390 nm.
Sequence: Mca-SEVKMDAEFR-Dap(Dnp)-NH2

Anti-Parallel Topology beta-Amyloid Modified Peptide II- Cat# 61805
This beta-amyloid peptide modification is attached to the amyloidogenic amino acids 14 to 23 fragment of beta-amyloid peptide in an anti-parallel topology.
Sequence: CHQKLVFFAEDYNGKHQKLVFFAED

beta-Amyloid (11-40)-Lys(biotin)-NH2- Cat# 62471
This amidated beta-Amyloid (11-40) is biotinylated at the C-terminus on the lysine side chain.
Sequence: EVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-K(Biotin)-NH2

beta-Amyloid (12-42)- Cat# 62452
This is amino acids 12 to 42 fragment of beta-Amyloid. This peptide shows significant fusogenic properties in unilamellar lipid vesicles.
Sequence: VHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA

beta-Amyloid (1-42); Sulforhodamine 101-labeled- Cat# 62221
This is a Sulforhodamine 101-labeled beta-Amyloid (1-42); Ex/Em=583 nm/601 nm.
Sequence: Sulforhodamine 101-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA

Beta-Amyloid (1-44)- Cat# 61966-01
This is the ß-Amyloid peptide amino acid residues 1 to 44. This sequence may be used in the ß-Amyloid structure and aggregation studies.
Sequence: DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATV

Beta-Amyloid (17-28)- Cat# 62447
This peptide is amino acids 17 to 28 fragment of beta-amyloid.
Sequence: LVFFAEDVGSNK

beta-Amyloid (22-40); amide- Cat# 62454
This amino acids 22 to 40 fragment of the beta-amyloid is used in beta-amyloid structure and aggregation studies.
Sequence: EDVGSNKGAIIGLMVGGVV-NH2

Beta-Amyloid (3-42)-Lys(Biotin); amide- Cat# 61959-01
This N-terminally truncated peptide corresponds to amino acids 3 to 42 fragment of beta-amyloid protein; biotinylated at the C-terminal lysine side chain.
Sequence: EFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-K(Biotin)-NH2

Betanova (BET)- Cat# 62531
Betanova (BET) is a three-stranded de novo-designed 20-residue peptide. The peptide is partially folded in water with the formation of a ?-hairpin involving residues 3 to 12. In a 40% TFE/water mixture; the formation of a second ?-hairpin is stabilized; and three-stranded conformation becomes more populated.
Sequence: RGWSVQNGKYTNNGKTTEGR

Bromoacetyl-beta-Amyloid (1-28)- Cat# 62441
This is amino acids 1 to 28 fragment of the beta-Amyloid peptide with bromoacetyl attached to the N-terminus.
Sequence: Bromoacetyl-DAEFRHDSGYEVHHQKLVFFAEDVGSNK

Cys-containing beta-Amyloid (1-40) Binding Peptide; biotin-labeled- Cat# 62429
This peptide containing flanking cysteines was shown to bind b-Amyloid (1-40) polymer form; but not monomeric beta-Amyloid (1-40). Such peptides are useful as carrier molecules to deliver therapeutic and diagnostic reagents to amyloid plaques. This peptide is biotinylated at the N-terminus.
Sequence: Biotin-AECDWGKGGRWRLWPGASGKTEACGP

DQ (65–79); Alpha Chain HLA II fragment- Cat# 62371
This amino acids 65 to 79 fragment derived from the alpha-chain HLA class II molecule DQA*03011 allele; blocks T cell proliferation and induces T cell apoptosis. The proliferating cell nuclear Ag (PCNA) is an intracellular ligand for this peptide. PCNA plays important roles in DNA replication; DNA repair; and control of cell cycle regulation. This fragment has antiproliferative effects on peripheral blood lymphocytes; particularly T cells.
Sequence: NIAVLKHNLNIVIKR

Obesity and Apoptosis Related Peptide; scrambled- Cat# 62198
This peptide was used as a negative control in obesity study; based on targeted induction of apoptosis in the vasculature of adipose tissue. The original obesity and apoptosis peptide was detected in the fat vasculature.
Sequence: CGDKAKGRC-GG-klaklakklaklak-NH2

CRGKA; Giardia Variable Surface Proteins Conserved Region- Cat# 62399
This peptide is the specific conserved region of the Giardia variable surface proteins (VSPs). Although VSPs differ in size and sequence; they are characterized by this highly conserved C-terminal membrane spanning region; a hydrophilic cytoplasmic tail with a conserved five amino acid CRGKA signature sequence. VSPs cover the trophozoite plasmalemma and are necessary for survival in the environment and host infection.
Sequence: CRGKA

Mycobacterium Tuberculosis Protein Ag85A-CD8- Cat# 62424
This is a T-cell immunodominant CD8 peptide of Ag85A Mycobacterium tuberculosis protein; MHC class I H-2Ld-restricted epitope. Because parenterally administered Mycobacterium bovis BCG vaccine confers only limited immune protection from pulmonary tuberculosis; intranasal administration of vector expressing AdAg85A represents an effective way to boost immune protection by parenteral BCG vaccination.
Sequence: MPVGGQSST

P. falciparum Liver-Stage Antigen 3-NRII (LSA3-NRII); (81-106)- Cat# 62549
This peptide is amino acids 81 to 106 fragment of the Plasmodium falciparum liver-stage antigen 3 (LSA3); a preerythrocytic antigen that induces protection against malaria in chimpanzees. The T-cell lines derived from infected chimpanzees show cytolytic activity against LSA3-NRII. The long-term CTL responses are particularly stable for this LSA3-NRII peptide; which is detected even 9 months after the final immunization.
Sequence: LEESQVNDDIFNSLVKSVQQEQQHNV

[Arg67]Bax H2-H3 (53-86); [R67] Helix 2-3 (53-86); mutant- Cat# 62330
This amino acids 53 to 86 fragment of Bax H2-H3 peptide; where Gly67 in the H2 region is replaced by an Arg. None of the cells injected with the mutant H2-H3 peptide became apoptotic; unlike the original peptide.
Sequence: DASTKKLSECLKRIRDELDSNMELQRMIAAVDTD

[Cys92]Bid BH3 (77-100); mouse- Cat# 62320
This peptide is amino acids 77 to 100 fragment of the to the murine Bid BH3 modification with Gln92 replaced by Cys92.
Sequence: ESQEEIIHNIARHLACIGDEMDHN

[Cys96]Bid BH3; mouse- Cat# 62321
This peptide is a modification of the amino acids 77 to 100 fragment of murine Bid BH3 peptide with Glu96 replaced by Cys.
Sequence: ESQEEIIHNIARHLAQIGDCMDHN

BAD Peptide; biotin-labeled- Cat# 62269
This BAD peptide is biotinylated at the N-terminus through 6-aminohexanoate (LC) as a spacer. Bad peptide is a pro-apoptotic member of the Bcl2 family. Dephosphorylated Bad forms heterodimers with Bcl-XL and Bcl-2; blocking their anti-apoptotic effects. Inactive Bad is phosphorylated at Ser112; Ser136; and Ser155. The phosphorylation status of Bad represents a fundamental checkpoint for apoptotic death or cell survival.
Sequence: Biotin-LC-AGAGRSRHSSYPAGT

Bak BH3 (67-87)- Cat# 62492
This is amino acids 67 to 87 fragment of the Bak BH3 multidomain protein. BH3-mediated dimerization does not consistently correlate with the apoptotic inducing activity of this protein. Bcl-B does not bind or suppress Bak as it binds Bax and suppresses apoptosis induced by over-expression of Bax.
Sequence: PSSTMGQVGRQLAIIGDDINR

Bax H2-H3 (53-86); Helix 2-3- Cat# 62283
This Bax H2-H3 peptide is amino acids 53 to 86 fragment of Bax which contains the BH3 helix plus residues in the downstream helix 3 (amino acids 74–81). Cultured cells injected with the H2-H3 peptide result in morphological changes consistent with apoptosis; including plasma membrane blebbing. H2-H3 peptide mimics Bax auto-activation.
Sequence: DASTKKLSECLKRIGDELDSNMELQRMIAAVDTD

Bax H3 (71-86); Helix 3 (71-86)- Cat# 62495
This amino acids 71 to 86 fragment of Bax H3 protein contains the BH3 helix plus residues in the downstream helix 3 (amino acids 74–81). Because apoptosis is regulated by a complicated series of interactions between Bcl-2 family proteins; both H2 and H3 regions of the protein are required for Bax activation.
Sequence: DSNMELQRMIAAVDTD

Bim BH3 (87-100)- Cat# 62484
This is amino acids 87 to 100 fragment of BAD BH3 protein.
Sequence: WIAQELRRIGDEFN

E7 (43–62); HPV Oncoprotein- Cat# 62011
This is amino acids 43 to 62 fragment of the E7 oncoprotein expressed in majority of the human papillomavirus 16 (HPV16)-induced cancers.
Sequence: GQAEPDRAHYNIVTFCCKCD

E7 (43–77); HPV Oncoprotein- Cat# 62012
This is amino acids 43 to 77 fragment of the oncoprotein E7; the peptide which may be employed for vaccine development against human papillomavirus 16 (HPV16)-induced tumors. It contains the oncoprotein E7 CTL epitope with its natural flanking sequences. The majority of HPV16-induced cancers express the HPV16-derived E6 and E7 oncoproteins; which are attractive targets for T cell-mediated immunotherapy.
Sequence: GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR

MAGE-A4 Antigen (230-239); human- Cat# 62364
This is amino acids 230 to 239 fragment of the melanoma antigen MAGE-A4 protein. MAGE-A4 belongs to the family of genes that are specifically expressed in a variety of tumors. MAGE-A4-derived peptides are presented by MHC molecules at the cell surface to cytotoxic T-lymphocytes. Because the HLA-A*0201:MAGE-A4 complex occurs only on tumor cells; it is considered to be an appropriate target for immunotherapy.
Sequence: GVYDGREHTV

NuBCP-9 A- Cat# 62323
This 9-amino acid Nur77-derived Bcl-2 converting peptide (NuBCP-9) may mimic behavior and functions of Nur77; orphan nuclear receptor transcription factor Nur77 (also known as NGFI-B and TR3). It translocates from nucleus to mitochondria where it has been demonstrated to bind antiapoptotic protein Bcl-2 and convert it from a cytoprotective to a cytodestructive protein; representing a phenotypic conversion mechanism.
Sequence: FSRSLHSLL

p53 Mutant Form (361-371); Pab 421- Cat# 62122
This amino acids 361 to 371 decapeptide is a fragment of the tumor protein p53 mutant form. It contains the PAb421 anti-p53 antibody epitope.
Sequence: KKGQSTSRHKK-NH2

p53 Tumor Suppressor (361-393); human- Cat# 62529
This peptide is amino acids 361 to 393 fragment of p53 tumor suppressor protein. p53 is a transcription factor that regulates cell cycle and functions as a tumor supressor.
Sequence: GSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD

Telomerase Reverse Transcriptase p572Y (TERT572Y)- Cat# 62413
This peptide belongs to the telomerase reverse transcriptase p572Y (TERT572Y). TERT572Y derived peptide vaccine against the non–small-cell lung cancer (NSCLC) is well tolerated and effective in eliciting a specific T cell immunity.
Sequence: RLFFYRKSV

L1FLCD (1173-1185)- Cat# 61660
This is amino acids 1173 to 1185 fragment of the L1 cytoplasmic domain (L1CD); containing the YRSL motif. The L1 subfamily of cell adhesion molecules (CAMs) has a highly conserved cytoplasmic domain that contains a tyrosine; followed by the alternatively spliced RSLE (Arg-Ser-Leu-Glu) sequence. Clathrin-mediated vesicular internalization of L1 via YRSL motif regulates adhesion and signaling. Tyr1176 of the YRSL motif is phosphorylated in vivo.
Sequence: FGEYRSLESDNEE

pALA; Polyalanine Peptide- Cat# 62114
This mostly polyalanine peptide (pALA) is widely used as a control. This poly-Ala-based peptide was also employed to study the anchor residues that are important for peptide binding to HLA-Cw*0304 in natural killer cell-mediated lysis research.
Sequence: AAADAAAAL

TAT-NSF700scr- Cat# 62209
This scrambled human immunodeficiency virus (HIV) transactivator of transcription (TAT) N-ethylmaleimide-sensitive factor (NSF) 700scr peptide is used as a control peptide to TAT-NSF700 peptide. It does not inhibit the disassembly activity of NSF in contrast to the TAT-NSF700 which plays a critical role in regulating exocytosis.
Sequence: YGRKKRRQRRRGGGIPPVYFSRLDLNLVVLLLAQL

TAT-NSF81scr Fusion Polypeptide ; scrambeled- Cat# 62237
This peptide contains the TAT domain fused to 20 of N-Ethyl-maleimide-sensitive factor81 (NSF81) in a scrambled sequence. TAT-NSF81scr is used to measure the effect of the active and control peptides upon NSF activities and exocytosis.
Sequence: YGRKKRRQRRR-GGG-QDGCKYFATDETIMKLSIAI

GGGGRGDS- Cat# 62350
This is a common RGD peptide used in material science to prepare alginate-based matrices.
Sequence: GGGGRGDS

GRGDK; FAM-labeled- Cat# 62525
This 5 residues modification of the cell adhesive GRGD peptide is labeled with FAM on the side chain of Lys; Ex/Em=490 nm/520 nm.
Sequence: GRGDK(5-FAM)

GRGDS; LC-biotin labeled- Cat# 62347
The GRGDS peptide contains the amino acid sequence Arg-Gly-Asp (RGD); which has been implicated as a recognition site in interactions between extracellular matrix (ECM) molecules and cell membrane receptors. RGD-containing synthetic peptides are known to inhibit attachment of endothelial cells to substrates. GRGDS peptide inhibits angiogenesis in serum-free collagen gel culture. This synthetic peptide mimics the cellular binding site of many adhesive proteins in the extracellular matrix and causes rounding and detachment of spread cells. This peptide is biotinylated through 6-aminohexanoate (LC) as a spacer.
Sequence: Biotin-LC-GRGDS

Integrin Binding Peptide- Cat# 62349
This is fibronectin derived; integrin-binding peptide. It may be used for PEG hydrogel preparation.
Sequence: Ac-GCGYGRGDSPG-NH2

C34; gp41 HIV Fragment- Cat# 62101
This C34 peptide; also known as HR2; belongs to the helical region of gp41 of HIV; C-terminal heptad repeat 2 (HR2) defined as C helix or C peptide. It is known that HIV-1 enters cells by membrane fusion; C34 gp41 peptide is a potent inhibitors of HIV-1 fusion.
Sequence: WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL

N36; HR1; gp41 HIV Fragment- Cat# 62100
This peptide belongs to the helical region of gp41 of HIV; an N-terminal heptad repeat 1 (HR1) defined as N helix or N peptide in various studies. HIV type 1 infects cells by fusing its membrane with the host cell membrane. Peptides from the N-heptad repeat region of the HIV gp41 protein can inhibit viral fusion.
Sequence: SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL

RANTES (11-22)- Cat# 62389
This peptide is derived from the N-loop region of RANTES; also known as CCL5. This chemokine shows antiviral activity. Certain chemokines including this protein; act as natural antagonists of human immunodeficiency virus (HIV) by blocking key viral coreceptors on the surface of susceptible cells.
Sequence: CFAYIARPLPRA

GALA; Pore-Forming Peptide- Cat# 62311
GALA is a 30 amino acid synthetic peptide with a glutamic acid-alanine-leucine-alanine (EALA) repeat. It also contains a histidine and tryptophan residue as spectroscopic probes. This peptide was designed to explore how viral fusion protein sequences interact with membranes. It was used to study the importance of the helix length; hydrophobicity; and hydrophobic moment on the formation; structure; and function of ion channels. The membrane-interacting properties of GALA have been extensively documented. Investigations with analogs of cytotoxic peptides clarify the importance of peptide charge and the role of particular amino acids or arrays of amino acids in the conformation; membrane-binding affinity; and pore-forming abilities of these toxins.
Sequence: WEAALAEALAEALAEHLAEALAEALEALAA

Optimal NHERF-1 PDZ1-Binding Motif- Cat# 62378
This peptide is an ideal Na exchanger regulatory factor-1 (NHERF-1) PDZ1-binding motif. NHERF-1 (also called “EBP50”) has two PDZ domains. PDZ domains have been found to be central organizers of protein complexes at the plasma membrane. Many transmembrane receptors and channels associate with PDZ domain-containing proteins. Such interactions may influence the function of receptors and channels. PDZ domains bind to the carboxyl-termini of target proteins; and some PDZ domains are capable of oligomerization to facilitate the formation of intracellular signaling complexes.
Sequence: VQDTRL

Skeletal Dihydropyridine Receptor (671-690)- Cat# 62390
This peptide is amino acids 671 to 690 fragment of dihydropyridine receptor. The dihydropyridine receptor II–III loop alters cardiac ryanodine receptor (RyR) channel activity in cytoplasmic Ca2+-dependent manner. The RyR Ca2+-release channel is located in the sarcoplasmic reticulum of striated muscle fibers.
Sequence: TSAQKAKAEERKRRKMSRGL

3Kp2; Class II MHC Molecule- Cat# 62553
This 15 amino acids peptide is presented by the mouse class II MHC molecule; IAb. This peptide together with the staining reagent is shown to bind with appropriate specificity to T-cell hybridomas.
Sequence: ASFEAQKAKANKAVD

Apolipoprotein B-100 (3136-3155); human- Cat# 62388
This peptide is amino acids 3136 to 3155 fragment of the apolipoprotein known as human apo B-100.
Sequence: KTTKQSFDLSVKAQYKKNKH

IL-8 Inhibitor- Cat# 62401
This hexapeptide; acetylated on the amino terminus and amidated on the carboxyl terminus; inhibits the specific binding of 125I-IL-8 to neutrophils. IL-8 is a member of the chemokine alpha subfamily that activates neutrophils and is chemotactic for these cells. IL-8 Inhibitor also suppresses the binding of macrophage inflammatory protein 2 (MIP 2) beta to neutrophils.
Sequence: Ac-RRWWCR-NH2

Immunodominant Mouse Minor Histocompatibility Antigen (MiHA)- Cat# 62402
This peptide is an immunodominant minor histocompatibility antigen presented by H-2Db on the surface of C57BL/6 mouse cells. It shows strong biologic activity in cytotoxic T lymphocyte sensitization assays at concentrations as low as 10 pM. This single dominant minor antigen can cause graft-versus-host disease.
Sequence: AAPDNRETF

LARFN5C (29-48); rat- Cat# 62219
This peptide is amino acids 29 to 48 fragment of 11 kDa ectodomain isoform of rat leukocyte common antigen-related (LAR) PTP receptor LARFN5C. Protein tyrosine phosphatase (PTP) receptors are important regulators of neurite outgrowth.
Sequence: PGPLQAKPFTILSPFLSSRC

Myelopeptide-2 (MP-2)- Cat# 62363
This immunoregulatory peptide was originally isolated from the conditioned medium of porcine bone marrow cell cultures. Myelopeptide 2 (MP-2) partly decreases the inhibitory effect of T suppressors in the culture of immune lymph node cells. MP-2 has been shown to restore the mitogen responsiveness of human T-lymphocytes inhibited by medium from HL-60 leukemia cells.
Sequence: LVVYPW

PIT (630–641); H+/K+-ATPase alpha-Chain Peptide (630–641)- Cat# 62088
This peptide is a fragment of the gastric hydrogen potassium ATPase or H+/K+ ATPase; which is the proton pump of the stomach. It was employed in several autoimmune gastritis studies.
Sequence: PITAKAIAASVG

Galanin Like Peptide (GALP); human- Cat# 61845-05
This 60-amino acid human galanin like peptide (GALP) has homology with rat and porcine GALP. It shows the GALR2-agonistic activity; and induces food intake.
Sequence: APAHRGRGGWTLNSAGYLLGPVLHLPQMGDQDGKRETALEILDLWKAIDGLPYSHPPQPS

Glutamate Receptor Endocytosis Inhibitor; GluR23Y- Cat# 62547
This GluR23Y peptide was used in ELISA cell-surface assay for the insulin-stimulated endocytosis of native AMPA receptors in cultured hippocampal neurons. GluR23Y prevented any insulin-induced reduction. The blockade of insulin action was observed when the GluR23Y peptide was delivered into neurons by fusing it to the membrane transduction domain of HIV-1.
Sequence: YKEGYNVYG

IRS-1-Derived Peptide; TAMRA-labeled- Cat# 61766
This is insulin receptor substrate 1 (IRS-1)-derived peptide labeled with TAMRA; Ex/Em = 542 nm/568 nm.
Sequence: 5-TAMRA-KKSRGDYMTMQIG-NH2

Rhodopsin (338-348); human; mice; rat; dog; bovine; pig- Cat# 62419
This peptide is amino acids 338 to 348 fragment of rhodopsin. Rhodopsin is a pigment of the retina that is responsible for the formation of the photoreceptor cells. Rhodopsin is a G-protein coupled receptor.
Sequence: KTETSQVAPA

Insulin alpha-chain (1-13)- Cat# 62405
This peptide is a fragment of the alpha-chain of insulin amino acids 1 to 13. The insulin a-chain epitope recognized by human T cells is posttranslationally modified
Sequence:

2 CDC25C; CHK1 and CHK2 Substrate; phosphorylated- Cat# 62324
This amino acids 206 to 225 fragment corresponds to the phosphatase CDC25C; phosphorylated at position Ser217. This peptide can be used for checkpoint kinases CHK1 and CHK2 assays.
Sequence: KKKVSRSGLYR-pS-PSMPENLNRPR-NH2

PrP (117-136); Protease-Resistant Prion Protein (117-136); hamster- Cat# 62112
This is amino acids 117 to 136 fragment of the protease-resistant prion protein. The accumulation of the protease-resistant isoform of prion protein PrP-res in the central nervous system is the pre-eminent neuropathological feature of transmissible spongiform encephalopathies (TSEs); a fatal neurodegenerative disease.
Sequence: AAGAVVGGLGGYMLGSAMSR

PrP (166-179); Protease-Resistant Prion Protein (166-179) (Biotin-LC); hamster- Cat# 62111
This peptide potently inhibits the protease-resistant prion protein (PrP-res) induced cell-free conversion of protease-sensitive (PrP-sen) to the protease-resistant state. The formation of PrP-res involves selective interactions between PrP-res and its normal protease-sensitive counterpart; PrP-sen. The accumulation of the protease-resistant isoform of prion protein PrP-res in the central nervous system is the pre-eminent neuropathological feature of transmissible spongiform encephalopathies (TSEs); a fatal neurodegenerative disease. This inhibitory peptide may mimic contact surfaces between PrP-res and PrP-sen and thereby serve as model of potential therapeutic agent for transmissible spongiform encephalopathies. This peptide is biotinylated through 6-aminohexanoate (LC) as a spacer at the N-terminus.
Sequence: Biotin-LC-VDQYNNQNNFVHDC

PrP (166-179); Protease-Resistant Prion Protein (166-179); hamster- Cat# 62110
This peptide potently inhibits the protease-resistant prion protein (PrP-res) induced cell-free conversion of protease-sensitive (PrP-sen) to the protease-resistant state. The formation of PrP-res involves selective interactions between PrP-res and its normal protease-sensitive counterpart; PrP-sen. The accumulation of the protease-resistant isoform of prion protein PrP-res in the central nervous system is the pre-eminent neuropathological feature of transmissible spongiform encephalopathies (TSEs); a fatal neurodegenerative disease. This inhibitory peptide may mimic contact surfaces between PrP-res and PrP-sen and thereby serve as model of potential therapeutic agent for transmissible spongiform encephalopathies.
Sequence: VDQYNNQNNFVHDC

PrP (200-223); Protease-Resistant Prion Protein (200-223); hamster- Cat# 62109
This peptide is amino acids 200 to 223 fragment of hamster protease-resistant prion protein. It inhibits the protease-resistant prion protein conversion of protease-sensitive (PrP-sen) to the protease-resistant state (PrP-res). The formation of PrP-res involves selective interactions between PrP-res and its normal protease-sensitive counterpart; PrP-sen. The accumulation of the protease-resistant isoform of prion protein PrP-res; in the central nervous system is the pre-eminent neuropathological feature of transmissible spongiform encephalopathies (TSEs); a fatal neurodegenerative disease.
Sequence: ETDIKIMERVVEQMCTTQYQKESQ

Cathepsin K substrate- Cat# 62368
This FRET peptide can be used to monitor selectively cathepsin K activity in physiological fluids and cell lysates. Abz-HPGGPQ-EDDnp [where Abz represents o-aminobenzoic acid and EDDnp represents N -(2;4-dinitrophenyl)-ethylenediamine]; a substrate initially developed for trypanosomal enzymes; is efficiently cleaved at the Gly-Gly bond by cathepsin K. This peptide is resistant to hydrolysis by cathepsins B; F; H; L; S and V; Ex/Em=340 nm/420 nm..
Sequence: Abz-HPGGPQ-EDDnp

Epsilon-C2/V1(74-79); epsilon PKC (74-79); C2 Domain- Cat# 62174
This amino acids 74 to 79 fragment of epsilon-C2/VI peptide belongs to the C2 regulatory domain of epsilon-protein kinase C (epsilon-PKC). The C2 domain is also called V1. This peptide increases MARCKS phosphorylation in wild type muscle cells and is found to be cardioprotective.
Sequence: CNGRKI

Epsilon-V1-2; epsilon-PKC Specific Inhibitor- Cat# 62295
This is a protein kinase C C2 (epsilon-PKC C2)-derived peptide; epsilon-PKC specific inhibitor; epsilon-V1-2. Peptides derived from epsilon-PKC C2 domain mediate PKC activity. Cysteine is added to the N-terminus for potential S-S bond formation with the carrier protein used in some applications.
Sequence: CEAVSLKPT

Jak3tide- Cat# 62537
This peptide is a substrate for Jak3. It may be used used in kinase assays. Jak3tide contains the phosphorylation site at Tyr7.
Sequence: GGEEEEYFELVKKKK

Mitogen-Activated Protein Kinase Kinase 2 (363-374); MAPK Kinase (363-374); human; monkey- Cat# 62400
This amino acids 363 to 374 fragment of the mitogen-activated protein kinase kinase 2 (MAPK kinase 2).
Sequence: LNQPGTPTRTAV

MK3; MAPK-Activated Protein Kinase 3- Cat# 62157
The MK3 belongs to the MK family that comprises 11 members that are generally activated by mitogens through the ERK1/2 kinase cascade (RSK1; RSK2; RSK3; RSK4; and MNK2); The mk3 gene encodes one transcript of 382 amino acids. MK3 appears to be ubiquitously expressed in the heart; skeletal muscle; and kidney tissues. MKs regulate gene expression at the transcriptional and post-transcriptional level; control cytoskeletal architecture and cell-cycle progression; and are implicated in inflammation and cancer. This sequence contains the docking motif for p38.
Sequence: DYDQVKIKDLKTSNNRLLNKRRKKQAGSSSAS

p120ctn; human- Cat# 61876
This is exon B-encoded protein sequence for human p120 catenin (p120ctn). The p120ctn protein is an efficient tyrosine kinase substrate implicated in both cell transformation by Src and in ligand-induced receptor signaling through various tyrosine kinase receptors. Exon B in p120ctn encodes this negatively charged peptide with 10 acidic amino acids out of a total of 29.
Sequence: QDEGQESLEEELDVLVLDDEGGQVSYPSM

Polo-like Kinase (134-140)- Cat# 62387
This amino acids 134 to 140 fragment of Polo-like kinase (Plk) contains the phosphorylation site at Ser137. Polo-like kinases are important regulators of cell cycle progression during M-phase.
Sequence: RRRSLLE

EBIP37; BIOTIN-LC- Cat# 62116
This sequence belongs to the nuclear receptor-interacting LXXLL peptides (where L is leucine and X any amino acid; also named the NR box). Transcriptional activation by nuclear receptors involves recruitment of co-activators that interact with receptors through their LXXLL motifs. The retinoid-related orphan receptor c (RORc) has been shown to function as a positive regulator of transcription. LXXLL peptides that interact with RORc efficiently antagonize RORc-mediated transcriptional activation. This peptide has the highest affinity for RORc. It is biotinylated at the N-terminus through 6-aminohexanoate (LC) as a spacer.
Sequence: BIOTIN-LC-TGGGVSLLLHLLNTEQGES

iNOS (507-531); human- Cat# 62254
This is amino acids 507 to 531 fragment of the inducible inflammation-related nitric oxide synthase (iNOS). It binds calmodulin avidly and appears to be fully active even at low ambient intracellular calcium levels in immunostimulated cells in contrast to the endothelial nitric oxide synthase (eNOS) which is intracellular calcium dependent.
Sequence: RPKRREIPLKVLVKAVLFACMLMRK

nNOS (725-747); rat- Cat# 62253
This is amino acids 725 to 747 fragment of neural NOS (nNOS) peptide; encompassing the calmodulin (CaM)-binding domain of rat constitutive cerebellar nitric oxide synthase (cNOS). It is activated as a short-term response to receptor-dependent calcium transients. The neural NOS (nNOS) and endothelial NOS (eNOS) are isoforms of cNOS.
Sequence: KRRAIGFKKLAEAVKFSAKLMGQ

Protein A Specific Ligand- Cat# 62376
This peptide is a specific ligand for protein A.
Sequence: GHHKHHGGG

Steroid Receptor Coactivator-1; SRC-1 (690-695)- Cat# 62257
This amino acids 690 to 695 fragment derived from the steroid receptor coactivator 1 (SRC1); also known as N2. The LXXLL motif serves as the interaction interface between the coactivator molecules and the ligand-dependent activation function (AF-2) located in the C-terminus of the nuclear receptor ligand-binding domain (LBD). Coactivator proteins interact with nuclear receptors in a ligand-dependent manner and augment transcription.
Sequence: LHRLLQ

TRPV4; rat (CT)- Cat# 61954
This peptide corresponds to the C-terminus of rat transient receptor potential vanilloid 4 (TRPV4); a member of the transient receptor potential family of ligand-gated ion channels. It was first identified as a mammalian osmotransducer. TRPV4 is a polymodal receptor activated by heat; phorbol esters; low pH and citrate; endocannabinoids; and arachidonic acid metabolites. TRPV4 is activated by physiological temperature in hippocampal neurons and thereby controls their excitability. Also a cation channel responsive to hypotonicity; it is expressed in a variety of tissues; including respiratory epithelium; salivary glands; and sweat glands. TRPV4 appears to be important in pathological pain conditions.
Sequence: CDGHQQGYAPKWRAEDAPL

OctTK-II Invertebrate Tachykinin- Cat# 61932
This novel invertebrate tachykinin like peptide (Inv-TK) OctTK-II containing the C-terminal consensus motif F-X-GLM-NH2 was characterized from salivary gland of Octopus vulgaris.
Sequence: KPPSSSEFVGLM-NH2

Alpha-2 Plasmin Inhibitor; Serpin Peptidase Inhibitor; Clade F (40-46); human- Cat# 62440
This peptide is the functional factor XIIIa substrate. Alpha-2-plasmin inhibitor; also termed primary plasmin inhibitor or antiplasmin; is the most potent and rapidly acting of the plasmin inhibitors and is thought to be important in the regulation of fibrinolysis in vivo. It has been used in assays to develop the potential of fibrin to promote nerve regeneration by enzymatically incorporating exogenous neurite-promoting heparin-binding peptides.
Sequence: NQEQVSP

Peptide 2A-54; Coagulation Factor IX (11-30); human- Cat# 62437
This peptide is amino acids 11 to 30 fragment of the human coagulation factor IX (hF.IX). In hemophilia B coagulation factor IX deficiency; lack of endogenous F.IX antigen expression; and other genetic factors may increase the risk of inhibitory antibody formation to functional coagulation factor IX. Formation of inhibitory antibodies is a serious complication of protein or gene replacement therapy for hemophilias. This peptide was created to develop a protocol for reducing inhibitor formation in gene therapy.
Sequence: TEQKRNVIRIIPHHNYNAAI

Complement C3a Anaphylatoxin (71-77); porcine- Cat# 62393
This peptide is amino acids 71 to 77 fragment of the complement C3a anaphylatoxin. A functionally active and potentially lethal fragment of the fifth component of complement (C5) is generated during complement activation in serum from animals of various species. This factor; termed the ``classical'' anaphylatoxin; was isolated from porcine serum and was identified chemically as the des-Arg derivative of the well-characterized C5a molecule.
Sequence: KPLGLAR

SNAP-25 (181-206)- Cat# 62315
This amino acids181 to 206 fragment is derived from the C-terminal helix of synaptosomal-associated protein of 25 kDa (SNAP-25). This peptide is able to rescue exocytosis from botulinum neurotoxin E (BoNT/E)-treated cells; albeit at higher concentrations than the full-length coil. This 26-amino acid peptide is incapable of forming an SDS-resistant SNARE complex.
Sequence: IMEKADSNKTRIDEANQRATKMLGSG

Vesicle-Associated Membrane Protein; VAMP (60-94)- Cat# 62312
This peptide is amino acids 60 to 90 fragment of the vesicle-associated membrane protein (VAMP) or synaptobrevin. VAMP controls the docking of synaptic vesicles with the synaptic membrane. This peptide is cleaved by botulinum neurotoxin BoNT at a single peptide bond between Gln76 and Phe77. Botulinum neurotoxins are metalloproteins with one zinc atom bound to the zinc binding motif of zinc endopeptidases.
Sequence: LSELDDRADALQAGASQFETSAAKLKRKYWWKNLK

Vesicle-Associated Membrane Protein; VAMP (77-94)- Cat# 62313
This is amino acids 77 to 90 fragment of the vesicle-associated membrane protein (VAMP) or synaptobrevin. It contains the evolutionarily conserved calmodulin- and phospholipid-binding domain. The calmodulin interaction site is positioned in a segment located immediately C-terminal to the botulinum (BoNT) and tetanus (TeTx) neurotoxins cleavage site (Q76-F77) and close to the transmembrane region.
Sequence: SQFETSAAKLKRKYWWKNLK

Hepatitis G Virus; HGV (2268-2276)- Cat# 62220
This is amino acids 2268 to 2276 fragment of the RNA virus; designated hepatitis G virus (HGV); derived from a plasma polyprotein of patients with chronic hepatitis. This virus is also known as GBV-C because of its close phylogenetic relationship to previously discovered primate viruses GBV-A and GBV-B.
Sequence: CDKCEARQE-NH2

HIV-1; Envelope Glycoprotein (187-203); biotin labeled- Cat# 62436
This peptide is amino acids 187 to 203 fragment of the HIV-1 envelope glycoprotein. It is labeled with biotin at the N-terminus and amidated at the C- terminus.
Sequence: Biotin-RGPGRAFVTIGKIGNMR-NH2

Influenza Virus Nucleoprotein (311-325)- Cat# 62420
This peptide is amino acids 311 to 325 fragment of the influenza virus nucleoprotein (NP). This bona fide MHC class II restricted epitope from influenza virus was used to study the host immunoresponse during the infection. This peptide elicits the strongest gamma interferon (IFN-gamma) production in the intracellular cytokine assays. It does not stimulate CD8 T-cells in mice.
Sequence: QVYSLIRPNENPAHK

Influenza Virus Nucleoprotein; NP (266-274)- Cat# 62421
This peptide is amino acids 266 to 274 fragment of the influenza virus nucleoprotein (NP). It is a strong I-Ab-binding epitope.
Sequence: LRGSVAHKS

Respiratory Synticial Virus (RSV) M2 Protein 10; bovine- Cat# 62391
This peptide is a fragment of the bovine respiratory synticial virus (RSV). It belongs to the Paramyxoviridae family of ssRNA negative-strand viruses.
Sequence: EWPPHALLVR

Respiratory Synticial Virus (RSV) M2 Protein 6- Cat# 62395
This peptide belongs to the respiratory syncytial virus (RSV)-specific; H-2Kd-restricted M2 protein fragment. It possesses the consensus sequence NYFEWPPHA for an H-2Kd-restricted T cell epitope; M226-34.
Sequence: CHFSHNYFEWPPHAL

Respiratory Synticial Virus (RSV) M2 Protein15- Cat# 62392
This peptide belongs to the respiratory syncytial virus (RSV)-specific; H-2Kd-restricted M2 protein fragment. It possesses the consensus sequence NYFEWPPHA for an H-2Kd-restricted T cell epitope; M226-34.
Sequence: HNYFEWPPHALLVRQ

Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry. Established in 1993, AnaSpec's headquarters and manufacturing facilities are located in San Jose, CA.